School of Biomedical Sciences & Pharmacy, Faculty of Health & Medicine, University of Newcastle, Newcastle, NSW, Australia.
Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW, Australia.
Am J Gastroenterol. 2019 Mar;114(3):429-436. doi: 10.1038/s41395-018-0377-0.
BACKGROUND: Subtle histopathologic features such as eosinophilia and increased mast cells have been observed in functional gastrointestinal disorders (FGIDs), including functional dyspepsia (FD) and the irritable bowel syndrome (IBS). The mechanisms that drive recruitment of these cells to the gastrointestinal tract remain unexplained, largely due to the heterogeneity in phenotypes among patients diagnosed with such conditions. We aimed to systematically review the literature and collate the evidence for immune activation in FD and IBS, and where possible, detail the nature of activation. METHODS: Seven literature databases were searched using the keywords: 'functional gastrointestinal disorder', FGID, 'functional dyspepsia', 'non-ulcer dyspepsia', 'idiopathic dyspepsia', 'irritable bowel syndrome', IBS and 'immun*'. RESULTS: Fifty-one papers reporting discordant immune features met the selection criteria for this review. Changes in lymphocyte populations, including B and T lymphocyte numbers and activation status were reported in IBS and FD, in conjunction with duodenal eosinophilia in FD and increased colonic mast cells in IBS. Increases in circulating α4+β7+ gut-homing T cells appear to be linked to the pathophysiology of both FD and IBS. Studies in the area are complicated by poor phenotyping of patients into subgroups and the subtle nature of the immune activity involved in FD and IBS. CONCLUSIONS: Alterations in proportions of gut-homing T lymphocytes in both FD and IBS indicate that a loss of mucosal homeostasis may drive the symptoms of FD and IBS. There is indirect evidence that Th17 responses may play a role in FGIDs, however the evidence for a Th2 immune phenotype in FD and IBS is limited. Although immune involvement is evident, large, well-characterised patient cohorts are required to elucidate the immune mechanisms driving the development of FGIDs.
背景:在功能性胃肠病(FGIDs)中,包括功能性消化不良(FD)和肠易激综合征(IBS),已经观察到细微的组织病理学特征,如嗜酸性粒细胞增多和肥大细胞增多。这些细胞被招募到胃肠道的机制仍未得到解释,主要是由于诊断为这种疾病的患者表型存在异质性。我们旨在系统地回顾文献,并整理 FD 和 IBS 中免疫激活的证据,并在可能的情况下详细说明激活的性质。
方法:使用关键词“功能性胃肠病”、FGID、“功能性消化不良”、“非溃疡性消化不良”、“特发性消化不良”、“肠易激综合征”和“免疫*”在七个文献数据库中搜索文献。
结果:报告了不一致的免疫特征的 51 篇论文符合本综述的选择标准。IBS 和 FD 中报告了淋巴细胞群体的变化,包括 B 和 T 淋巴细胞数量和激活状态,同时伴有 FD 中的十二指肠嗜酸性粒细胞增多和 IBS 中的结肠肥大细胞增多。循环中 α4+β7+肠道归巢 T 细胞的增加似乎与 FD 和 IBS 的病理生理学有关。该领域的研究受到患者分为亚组的表型不良和 FD 和 IBS 中涉及的免疫活性的细微性质的影响。
结论:FD 和 IBS 中肠道归巢 T 淋巴细胞比例的改变表明,黏膜稳态的丧失可能导致 FD 和 IBS 的症状。有间接证据表明 Th17 反应可能在 FGIDs 中起作用,然而 FD 和 IBS 中 Th2 免疫表型的证据有限。尽管免疫参与是明显的,但需要大的、特征良好的患者队列来阐明驱动 FGIDs 发展的免疫机制。
Gut. 2015-7-20
Am J Gastroenterol. 2011-1-18
Korean J Helicobacter Up Gastrointest Res. 2024-12
Cell Mol Gastroenterol Hepatol. 2025
J Inflamm Res. 2025-2-4
Nat Rev Gastroenterol Hepatol. 2025-4